Chronic Somogyi rebound
Chronic Somogyi rebound is a contested explanation of phenomena of elevated blood sugars in the morning. Also called the Somogyi effect and posthypoglycemic hyperglycemia, it is a rebounding high blood sugar that is a response to low blood sugar. When managing the blood glucose level with insulin injections, this effect is counter-intuitive to insulin users who experience high blood sugar in the morning as a result of an overabundance of insulin at night.
This theoretical phenomenon was named after Dr. Michael Somogyi, a Hungarian-born professor of biochemistry at the Washington University and Jewish Hospital of St. Louis, who prepared the first insulin treatment given to a child with diabetes in the USA in October 1922. Somogyi showed that excessive insulin makes diabetes unstable and first published his findings in 1938.
A person with type 1 diabetes should balance insulin delivery to manage their blood glucose level. Occasionally, insufficient insulin can result in hyperglycemia. The appropriate response is to take a correction dose of insulin to reduce the blood sugar level and to consider adjusting the insulin regimen to deliver additional insulin in the future to prevent hyperglycemia. Conversely, excessive insulin delivery may result in hypoglycemia. The appropriate response is to treat the hypoglycemia and to consider adjusting the regimen to reduce insulin in the future.
Somogyi and others have claimed that if prolonged hypoglycemia is untreated, then stress due to low blood sugar can result in a high blood glucose rebound. The physiological mechanisms driving the rebound are defensive. When the blood glucose level falls below normal, the body responds by releasing the endocrine hormone glucagon as well as the stress hormones epinephrine, cortisol and growth hormone. Glucagon facilitates release of glucose from the liver that raises the blood glucose immediately, and the stress hormones cause insulin resistance for several hours, sustaining the elevated blood sugar.
The first line of defense in preventing chronic Somogyi rebound is additional blood glucose testing. Continuous blood glucose monitoring is the preferred method to detect and prevent the Somogyi rebound, but this technology is not yet widely used. Alternatively, testing blood sugar more often, 8 to 10 times daily with a traditional blood glucose meter, facilitates detecting the low blood sugar level before such a rebound occurs.
Testing occasionally during the middle of the night is also important, particularly when high waking blood sugars are found, to determine if more insulin is needed to prevent hyperglycemia or if less insulin is needed to prevent such a rebound.
Sometimes a person with diabetes will experience the Somogyi rebound when awake and notice symptoms of the initial low blood sugar or symptoms of the rebound. At night, waking with a night sweat (perhaps combined with a rapid heart rate) is a symptom of the adrenaline and rebound. Unfortunately, the evidence shows that patients with type 1 diabetes do not normally wake during nocturnal hypoglycemic episodes .
While reviewing log data of blood glucose after the fact, signs of Somogyi rebound should be suspected when blood glucose numbers seem higher after the insulin dosage has been raised, particularly in the morning.
In theory, avoidance is simply a matter of preventing hyperinsulinism. In practice, the difficulty for a diabetic person to aggressively dose insulin to keep blood sugars levels close to normal and at the same time constantly adjust the insulin regimen to the dynamic demands of exercise, stress, and wellness can practically assure occasional hyperinsulinism. The pharmacokinetic imperfections of all insulin replacement regimens is a severe limitation.
Some practical behaviors which are useful in avoiding chronic Somogyi rebound are:
- frequent blood glucose monitoring (8–10 times daily);
- continuous blood glucose monitoring;
- logging and review of blood glucose values, searching for patterns of low blood sugar values;
- conservative increases in insulin delivery;
- awareness to the signs of hypoglycemia;
- awareness to hyperglycemia in response to increased delivery of insulin;
- use of appropriate types of insulin (long-acting, short-acting, etc.) in appropriate amounts.
Although this theory is well known among clinicians and individuals with diabetes, there is little scientific evidence to support it. Clinical studies indicate that a high fasting glucose in the morning is more likely because the insulin given on the previous evening fails to last long enough. Studies from 2007 onwards using continuous glucose monitoring show that a high glucose in the morning is not preceded by a low glucose during the night. Furthermore, many individuals with hypoglycemic episodes during the night don't wake due to a failure of release of epinephrine during nocturnal hypoglycemia. Thus, Somogyi's theory is not assured and may be refuted.
- http://www.ucdenver.edu/academics/colleges/medicalschool/centers/BarbaraDavis/Documents/book-understandingdiabetes/ud06.pdf, Understanding Diabetes a.k.a. The Pink Panther Book by H. Peter Chase, chapter 6 page 47.
- Michael Somogyi (www.whonamedit.com)
(As of 2011-05-28, the electronic text is not open access).
- Attention: This template (Template:Tl) is deprecated. To cite the publication identified by doi:10.2337/diabetes.37.12.1608, please use Template:Tl with Template:Para instead.
- Gale, EA, Kurtz, AB, Tattersall, RB. In search of the Somogyi effect. Lancet 2:279-282, 1980, PMID 6105438
- Guillod, L., Comte-Perret, S., Monbaron, D., Gaillard, R. C., Ruiz, J. Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring? Diabetes Metab, 2007: 33: 360-365, PMID 17652003
- Matyka, KA, Crowne, EC, Havel, PJ, Macdonald, IA, Matthews, D, Dunger, DB. Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 22:1144-1150, 1999, PMID 10388980
Michael Cooperman, MD; Chief Editor: George T Griffing, MD. Somogyi Phenomenon. Medscape Dec 15, 2011.
Articles on Chronic Somogyi rebound
|Govt. policies / Guidelines|
Media articles Chronic Somogyi rebound
|Patient Resources / Community|
Evidence Based Medicine
|Healthcare Provider Resources|
|News on Chronic Somogyi rebound|
Definition of Chronic Somogyi rebound
|Flickr on Chronic Somogyi rebound|
Books on the topic
|Facebook posts Chronic Somogyi rebound|
Continuing medical education (CME)
|Tweets about Chronic Somogyi rebound|
|Pintest on Chronic Somogyi rebound||Commentary & #Chronic Somogyi rebound|
World's largest food, health, weight loss, wellnesspedia and encyclopedia
If you are a medical professional or an expert in any field of medicine, please join us in building the world's largest weight loss and wellness encyclopedia created by experts in the field, not by the crowd. WikiMD is sponsored by W8MD weight loss, sleep and medical aesthetic centers
W8MD Weight Loss, Sleep & Medical Aesthetic Centers
Since its inception in 2011, W8MD’s insurance physician weight loss program has successfully helped thousands of patients succeed in not only losing weight but also keep it off with an ongoing maintenance plan.
FANTASTIC PROGRAM. TRULY A LIFE CHANGER. D.M. LOST 100 LBS^^
^^Individual results may vary.
W8MD weight loss, sleep and medical spa blogs
Support our sponsors
W8MD weight loss, sleep and medspa centers sponsors WikiMD.
W8MD's Locations for losing weight, sleeping better and looking your best
King of Prussia
Other W8MD blogs
2632 E 21st Street Ste L2 Brooklyn New York 11235.
W8MD's insurance weight loss program
W8MD can help?
Dr Tumpati is a board certified physician with significant practice experience in managing sleep disorders, internal medicine, aesthetic and obesity medicine. As one of the few physicians that have the privilege of a fellowship training in Obesity Medicine, Dr Tumpati is very passionate about educating the public and physicians about how some of the nutritional concepts were misunderstood. As the founder of W8MD Weight Loss, Sleep and MedSpa centers, Dr Tumpati is the medical director for the New York, New Jersey and Pennsylvania locations and commutes weekly between the locations.